Angry Gut: Irritable Bowel Syndrome
DOI:
https://doi.org/10.51985/JBUMDC2021112Keywords:
Constipation, Diarrhea, Irritable bowel syndrome, ROME IV criteria.Abstract
Irritable bowel syndrome (IBS) is a functional disorder of the intestine characterized by abdominal pain and altered bowel
habits. At present, no biological marker has been identified. Hence, the disease is clinically assessed on the basis of the
symptoms according to ROME IV criteria. Epidemiological data revealed that the prevalence of IBS varies widely around
the world, and more thorough research is needed to pinpoint any discrepancies that may exist between countries, as well
as possible reasons. Both pharmacological and non-pharmacological therapy is being used in order to treat IBS. There is
no specific treatment for irritable bowel disease that has come across the patients and only possible measures have been
taken to treat the severity of symptoms. Symptomatic treatment with spasmolytic agent like mebeverine has been considered
a standard therapy to relieve pain but to deal with constipation and diarrhea different treatment modalities have been adopted
by the physician
References
Ng QX, Soh AY, Loke W, Lim DY, Yeo WS. The role of
inflammation in irritable bowel syndrome (IBS). Journal of
inflammation research. 2018;11:345. doi: 10.2147/JIR.S174982
Ford AC. Commentary: estimating the prevalence of IBS
globally—past, present and future. Alimentary pharmacology
& therapeutics. 2020;51(1):198-9.https://doi.org/
1111/apt.15508
Vork L, Weerts ZZ, Mujagic Z, Kruimel JW, Hesselink MA,
Muris JW, Keszthelyi D, Jonkers DM, Masclee AA. Rome
III vs Rome IV criteria for irritable bowel syndrome: A
comparison of clinical characteristics in a large cohort study.
Neurogastroenterology & Motility. 2018;30(2):e13189.https://
doi.org/10.1111/nmo.13189
Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable
bowel syndrome. The lancet Gastroenterology & hepatology.
;1(2):133-46. https://doi.org/10.1016/S2468-
(16)30023-1
El-Salhy M, Hausken T, Gilja OH, Hatlebakk JG. The possible
role of gastrointestinal endocrine cells in the pathophysiology
of irritable bowel syndrome. Expert review of gastroenterology
& hepatology. 2017;11(2):139-48. https://doi.org/10.1080/
2017.1269601
Masuy I, Van Oudenhove L, Tack J, Biesiekierski JR. Effect
of intragastric FODMAP infusion on upper gastrointestinal
motility, gastrointestinal, and psychological symptoms in
irritable bowel syndrome vs healthy controls. Neurogastroenterology & Motility. 2018;30(1):e13167. https://doi.org/
1111/nmo.13167
Barros LL, Farias AQ, Rezaie A. Gastrointestinal motility
and absorptive disorders in patients with inflammatory bowel
diseases: Prevalence, diagnosis and treatment. World journal
of gastroenterology. 2019;25(31):4414. doi: 10.3748/wjg.v25.
i31. 4414
Fuentes IM, Christianson JA. Ion channels, ion channel
receptors, and visceral hypersensitivity in irritable bowel
syndrome. Neurogastroenterology & Motility.
;28(11):1613-8. https://doi.org/10.1111/nmo.12979
Farzaei MH, Bahramsoltani R, Abdollahi M, Rahimi R. The
role of visceral hypersensitivity in irritable bowel syndrome:
pharmacological targets and novel treatments. Journal of
Neurogastroenterology and Motility. 2016;22(4):558. doi:
5056/ jnm16001
Sasaki A, Sato N, Suzuki N, Kano M, Tanaka Y, Kanazawa
M, Aoki M, Fukudo S. Associations between single-nucleotide
polymorphisms in corticotropin-releasing hormone-related
genes and irritable bowel syndrome. PloS one. 2016 Feb
;11(2):e0149322. https://doi.org/ 10.1371/journal.pone.
Zhu S, He M, Liu Z, Qin Z, Wang Z, Duan L. Shared genetic
susceptibilities for irritable bowel syndrome and depressive
disorder in Chinese patients uncovered by pooled wholeexome sequencing. Journal of advanced research. 2020;23:113-
https://doi.org/10.1016/j. jare.2020.01.016
Henström M, D’Amato M. Genetics of irritable bowel
syndrome. Molecular and cellular pediatrics. 2016;3(1):1-5.
https://doi.org/10.1186/s40348-016-0038-6
Bhattarai Y, Muniz Pedrogo DA, Kashyap PC. Irritable bowel
syndrome: a gut microbiota-related disorder?. American
Journal of Physiology-Gastrointestinal and Liver Physiology.
; 312(1):G52-62. https://doi.org/10.1152/ajpgi.00338.2016
Harris LA, Baffy N. Modulation of the gut microbiota: a focus
on treatments for irritable bowel syndrome. Postgraduate
medicine. 2017;129(8):872-88. https://doi.org/10.1 080/0
2017.1383819
Wang Z, Xu CM, Liu YX, Wang XQ, Zhang L, Li M, Zhu
SW, Xie ZJ, Wang PH, Duan LP, Zhu HQ. Characteristic
dysbiosis of gut microbiota of Chinese patients with diarrheapredominant irritable bowel syndrome by an insight into the
pan-microbiome. Chinese medical journal. 2019;132(8):889.
https://doi.org/10.1097/CM9.0000000000000192
Volta U, Pinto-Sanchez MI, Boschetti E, Caio G, De Giorgio
R, Verdu EF. Dietary triggers in irritable bowel syndrome: is
there a role for gluten?. Journal of Neurogastroenterology
and Motility. 2016;22(4):547.doi: 10.5056/jnm16069
Moser G, Fournier C, Peter J. Intestinal microbiome-gut-brain
axis and irritable bowel syndrome. Wiener Medizinische
Wochenschrift. 2018;168(3):62-6. https://doi.org/10.1007/
s10354-017-0592-0
Pellissier S, Bonaz B. The place of stress and emotions in the
irritable bowel syndrome. Vitamins and hormones. 2017;
:327-54. https://doi.org/10.1016/bs.vh.2016.09.005
Peleman C, Camilleri M, Busciglio I, Burton D, Donato L,
Zinsmeister AR. Colonic transit and bile acid synthesis or
excretion in patients with irritable bowel syndrome–diarrhea
without bile acid malabsorption. Clinical Gastroenterology
and Hepatology. 2017;15(5):720-7. https://doi.org/10.1016/j
.cgh.2016.11.012
0. Jeffery IB, Das A, O’Herlihy E, Coughlan S, Cisek K, Moore
M, Bradley F, Carty T, Pradhan M, Dwibedi C, Shanahan F.
Differences in fecal microbiomes and metabolomes of people
with vs without irritable bowel syndrome and bile acid
malabsorption. Gastroenterology. 2020;158(4):1016-28.
https://doi.org/10.1053/j.gastro.2019.11.301
Barbara G, Cremon C, Azpiroz F. Probiotics in irritable bowel
syndrome: Where are we?. Neurogastroenterology & Motility.
;30(12):e13513. https://doi.org/10.1111/nmo.13513
Principi N, Cozzali R, Farinelli E, Brusaferro A, Esposito S.
Gut dysbiosis and irritable bowel syndrome: The potential
role of probiotics. Journal of Infection. 2018;76(2):111-20.
https://doi.org/10.1016/j.jinf.2017.12.013
Oh JH, Jang YS, Kang D, Chang DK, Min YW. Efficacy and
safety of new Lactobacilli probiotics for unconstipated irritable
bowel syndrome: A randomized, double-blind, placebocontrolled trial. Nutrients. 2019;11(12):2887. https://doi.org/
3390/nu11122887
Shastri MD, Chong WC, Vemuri R, Martoni CJ, Adhikari S,
Bhullar H, Kunde D, Tristram SG, Eri RD. Streptococcus
thermophilus UASt-09 upregulates goblet cell activity in
colonic epithelial cells to a greater degree than other probiotic
strains. Microorganisms. 2020;8(11):1758. https://doi.org/
3390 /microorganisms8111758
Gayathri R, Aruna T, Malar S, Shilpa B, Dhanasekar KR.
Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an
add-on therapy for irritable bowel syndrome. International
journal of colorectal disease. 2020;35(1):139-45. https://doi.org
/10.1007/s00384-019-03462-4
Harper A, Naghibi MM, Garcha D. The role of bacteria,
probiotics and diet in irritable bowel syndrome. Foods. 2018
;7(2):13. https://doi.org/10.3390/foods7020013
Barbalho SM, Goulart RD, Araújo AC, Guiguer ÉL, Bechara
MD. Irritable bowel syndrome: a review of the general aspects
and the potential role of vitamin D. Expert review of
gastroenterology & hepatology. 2019;13(4):345-59.
https://doi.org/ 10.1080/17474124.2019.1570137
Nwosu BU, Maranda L, Candela N. Vitamin D status in
pediatric irritable bowel syndrome. PLoS One.
;12(2):e0172183. https://doi.org/10.1371/ journal.
pone.0172183
Jalili M, Vahedi H, Poustchi H, Hekmatdoost A. Effects of
vitamin D supplementation in patients with irritable bowel
syndrome: a randomized, double-blind, placebo-controlled
clinical trial. International journal of preventive medicine.
;10. doi: 10.4103/ijpvm.IJPVM_512_17
Hong SW, Chun J, Park S, Lee HJ, Im JP, Kim JS. Aloe vera
is effective and safe in short-term treatment of irritable bowel
syndrome: a systematic review and meta-analysis. Journal of
neurogastroenterology and motility. 2018;24(4):528. doi:
5056/jnm18077
Dimidi E, Whelan K. Food supplements and diet as treatment
options in irritable bowel syndrome. Neurogastroenterology
& Motility. 2020; 32(8):e13951. https://doi.org/10. 1111/
nmo.13951
Weerts ZZ, Masclee AA, Witteman BJ, Clemens CH, Winkens
B, Brouwers JR, Frijlink HW, Muris JW, De Wit NJ, Essers
BA, Tack J. Efficacy and safety of peppermint oil in a
randomized, double-blind trial of patients with irritable bowel
syndrome. Gastroenterology. 2020;158(1):123-36. https://doi.
org/10.1053/j.gastro.2019.08.026
Weerts ZZ, Keszthelyi D, Vork L, Aendekerk NC, Frijlink
HW, Brouwers JR, Neef C, Jonkers DM, Masclee AA. A
novel ileocolonic release peppermint oil capsule for treatment
of irritable bowel syndrome: A phase I study in healthy
volunteers. Advances in therapy. 2018;35(11):1965-
https://doi.org/10.1007/s12325-018-0802-1
Cash BD, Epstein MS, Shah SM. A novel delivery system of
peppermint oil is an effective therapy for irritable bowel
syndrome symptoms. Digestive diseases and sciences.
;61(2):560-71.https://doi.org/10.1007/s10620-015-3858-
Kinsinger SW. Cognitive-behavioral therapy for patients with
irritable bowel syndrome: current insights. Psychology research
and behavior management. 2017;10:231.doi: 10.2147/ PRBM.
S120817
El-Salhy M, Ystad SO, Mazzawi T, Gundersen D. Dietary
fiber in irritable bowel syndrome. International journal of
molecular medicine. 2017;40(3):607-13. https://doi.org
/10.3892/ijmm.2017.3072
Zhuang Z, Chen M, Niu J, Qu N, Ji B, Duan X, Liu Z, Liu
X, Wang Y, Zhao B. The manufacturing process of kiwifruit
fruit powder with high dietary fiber and its laxative effect.
Molecules. 2019;24(21):3813. https://doi. org/10.3390
/molecules 24213813
Taylor AM, Holscher HD. A review of dietary and microbial
connections to depression, anxiety, and stress. Nutritional
neuroscience. 2020;23(3):237-50. https://doi.org/10.1080/
X.2018.1493808
Oskouie FH, Vahedi H, Shahrbaf MA, Sadeghi A, Rashidkhani
B, Hekmatdoost A. Dietary fiber and risk of irritable bowel
syndrome: a case-control study. Gastroenterology and
hepatology from bed to bench. 2018;11(Suppl 1):S20. doi:
1097/MD.0000000000027541
Casado-Bedmar M, Keita ÅV. Potential neuro-immune
therapeutic targets in irritable bowel syndrome. Therapeutic
advances in gastroenterology. 2020;13:1756284820910630.
https://doi.org/10.1177/1756284820910630
Garg P. Inflammation in Irritable Bowel Syndrome (IBS):
Role of Psyllium Fiber Supplementation in Decreasing
Inflammation and Physiological Management of IBS. Turk
J Gastroenterol. 2021;32(1):108-10. DOI: 10.5152/ tjg.2020.
Radovanovic-Dinic B, Tesic-Rajkovic S, Grgov S, Petrovic
G, Zivkovic V. Irritable bowel syndrome-from etiopathogenesis
to therapy. Biomedical Papers of the Medical Faculty of
Palacky University in Olomouc. 2018;162(1). https://doi. org/
5507/bp.2017.057
Chen L, Ilham SJ, Feng B. Pharmacological approach for
managing pain in irritable bowel syndrome: a review article.
Anesthesiology and pain medicine. 2017;7(2).doi:
5812/aapm.42747
Yang Y, Fang J, Guo X, Dai N, Shen X, Yang Y, Sun J,
Bhandari BR, Reasner DS, Cronin JA, Currie MG. Linaclotide
in irritable bowel syndrome with constipation: a phase 3
randomized trial in China and other regions. Journal of
gastroenterology and hepatology. 2018;33(5):980-9.
https://doi.org/10.1111/jgh.14086
Song KH, Jung HK, Kim HJ, Koo HS, Kwon YH, Shin HD,
Lim HC, Shin JE, Kim SE, Cho DH, Kim JH. Clinical practice
guidelines for irritable bowel syndrome in Korea. Journal of
neurogastroenterology and motility. 2018;24(2):197. doi:
5056/jnm17145
Barney VA, Hernández AF. The role of antispasmodics in
managing irritable bowel syndrome. Rev Colomb
Gastroenterol. 2019;34(3):267-73. https://doi.org/10.22516
/25007440.309
Evangelista S, Traini C, Vannucchi MG. Otilonium Bromide:
a drug with a complex mechanism of action. Current pharmaceutical design. 2018;24(16):1772-9. https://doi.org/ 10.2174/
Schmulson MJ, Chiu-Ugalde J, Sáez-Ríos A, López-Colombo
A, Mateos-Pérez GJ, Remes-Troche JM, Sobrino-Cossio S,
Soto-Pérez JC, de la Cuesta JL, Teramoto-Matsubara OT,
López-Alvarenga JC. Efficacy of the combination of
pinaverium bromide 100 mg plus simethicone 300 mg in
abdominal pain and bloating in irritable bowel syndrome: a
randomized, placebo-controlled trial. Journal of Clinical
Gastroenterology. 2020;54(4):e30. https://doi.org/10.1097
/MCG.0000000000001242
Heghes SC, Vostinaru O, Rus LM, Mogosan C, Iuga CA,
Filip L. Antispasmodic effect of essential oils and their
constituents: A review. Molecules. 2019;24(9):1675.
https://doi.org/10.3390/molecules24091675
Hatami K, Kazemi Motlagh A, Ajdarkosh H, Zargaran A,
Karimi M, SHAMSHIRI A, GHADIR M. Comparing the
Efficacy of Cumin Sofouf With Mebeverine on Irritable Bowel
Syndrome Severity and Quality of Life: A Double-blind
Randomized Clinical Trial. Crescent Journal of Medical and
Biological Sciences. 2020;7(2):186-94. eISSN 2148-9696
Chakraborty DS, Hazra A, Sil A, Pain S. Will controlled
release mebeverine be able to surpass placebo in treatment
of diarrhoea predominant irritable bowel syndrome?. Journal
of family medicine and primary care. 2019;8(10):3173. doi:
4103/jfmpc.jfmpc_522_19
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Izrum Shafi Rajput, Syed Ijaz Hussain Zaidi, Muhammad Sajid Abbas Jaffri, Syed Wajahat Hasib, Kashif Razaq
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0 
